RESOURCES & SUPPORT

With your help, VIBERZI continues to assist patients suffering from IBS-D – but there’s more we can do for them – and you! Below are resources and tools that can be utilized by your practice.

TOOLS FOR YOUR PRACTICE

Does your practice need VIBERZI samples? Want to hear how your peers are treating their patients with IBS-D discomfort? Here are some resources for you and your practice:

REQUEST SAMPLES

Need product samples for your practice?

ORDER HERE >

Not eligible where prohibited by law.

THE IBS-D(ECODED) PODCAST

IBS Decoded Logo

Hear from the experts (and their patients) in this 3-part peer-to-peer series.

LISTEN NOW >

PATIENT SAVINGS

Savings Card Icon

Eligible patients can save on their prescription through the VIBERZI Savings Program. Based on their healthcare coverage, their VIBERZI prescription could cost as little as:

$30*

FOR A 30-DAY PRESCRIPTION

OR
$30*

FOR A 90-DAY PRESCRIPTION

That’s equivalent to 35¢ per day for the 90-day offer!


Your patients have two ways to enroll in the VIBERZI Savings Program:

*Maximum savings limit applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. This offer is not valid for cash-paying patients. Please click here for full Program Terms, Conditions, and Eligibility Criteria.

Message and data rates apply. Reply HELP for help; reply STOP to cancel. Message frequency depends on user. Consent not required to purchase goods/services.

PRIOR AUTHORIZATION

To assist in making the prior authorization (PA) process easier, here are two services for your practice to consider using when prescribing VIBERZI to eligible patients:

Covermymeds logo

A tool that your practice and pharmacies can use to help complete PA requests. Visit covermymeds.com/main or call 1-866-452-5017 to learn more.

PARX Solutions logo

A web-based service, including a support staff, that helps physicians process and manage their PAs through to completion. Visit parxsolutions.com or call 1-866-725-7279 to learn more.

DID YOU KNOW?

95% of VIBERZI commercial LIVES HAVE COVERED OR BETTER ACCESS1‡

AbbVie is committed to providing ongoing support to your patients and practice. To learn more, contact our Medical Information team here.

Managed Markets Insight & Technology, LLC, a trademark of MMIT Database, as of February 2023. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Formulary coverage does not imply efficacy or safety.

Data are not a guarantee of coverage. Actual benefits determined by respective plan administrators, insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurer. Formulary coverage does not imply efficacy or safety.

PATIENT SAVINGS PROGRAM

Savings cards available for your patients!

LEARN MORE >

VIBERZI SAMPLES

Free samples available for your patients!

ORDER HERE >

Not available where prohibited by law.

SUPPORT FOR YOU & YOUR PATIENTS

Ongoing educational updates about IBS-D!

DISCOVER MORE >
IMPORTANT SAFETY INFORMATION
Indications and Usage

VIBERZI® (eluxadoline) CIV is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Contraindications

VIBERZI is contraindicated in patients:

  • Without a gallbladder.
  • With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
  • With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
  • With a known hypersensitivity reaction to VIBERZI.
  • With severe hepatic impairment.
  • With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pancreatitis:
  • Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.
Sphincter of Oddi Spasm:
  • There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.
Hypersensitivity Reactions:
  • In postmarketing experience, serious hypersensitivity reactions (including anaphylaxis) have been reported following VIBERZI administration. Some of these reactions occurred after the first one or two doses of VIBERZI.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.
Constipation:
  • Constipation, sometimes requiring hospitalization, has been reported following VIBERZI administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported. Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they experience severe constipation. Avoid use with other drugs that may cause constipation.
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Please also see full Prescribing Information.